BridgeBio Pharma Inc [BBIO] stock is trading at $37.22, up 7.05%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BBIO shares have gain 12.75% over the last week, with a monthly amount glided 1.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 04, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $46 on the stock. BMO Capital Markets initiated its recommendation with a Market Perform and recommended $37 as its price target on January 31, 2024. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $58. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating.
BridgeBio Pharma Inc [BBIO] stock has fluctuated between $21.62 and $39.47 over the past year. Currently, Wall Street analysts expect the stock to reach $45.5 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $37.22 at the most recent close of the market. An investor can expect a potential return of 22.25% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 221.90M for the trailing twelve months, which represents a growth of 237.08%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.66%, Pretax Profit Margin comes in at -2.44%, and Net Profit Margin reading is -2.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is 0.44 and Total Capital is -0.67. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.37 points at the first support level, and at 33.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.51, and for the 2nd resistance point, it is at 39.79.
Ratios To Look Out For
For context, BridgeBio Pharma Inc’s Current Ratio is 4.67. In addition, the Quick Ratio stands at 4.67 and the Cash Ratio stands at 16.48. Considering the valuation of this stock, the price to sales ratio is 31.90.
Transactions by insiders
Recent insider trading involved Valantine Hannah, Director, that happened on Mar 06 ’25 when 12875.0 shares were sold. 10% Owner, KKR Genetic Disorder L.P. completed a deal on Mar 05 ’25 to sell 6.0 million shares. Meanwhile, Director HANNAH A VALANTINE bought 12875.0 shares on Mar 06 ’25.
